肠易激综合征的治疗方法:新旧策略。

IF 3.2 Q2 Pharmacology, Toxicology and Pharmaceutics
Paolo Usai-Satta, Massimo Bellini, Mariantonia Lai, Francesco Oppia, Francesco Cabras
{"title":"肠易激综合征的治疗方法:新旧策略。","authors":"Paolo Usai-Satta,&nbsp;Massimo Bellini,&nbsp;Mariantonia Lai,&nbsp;Francesco Oppia,&nbsp;Francesco Cabras","doi":"10.2174/1574884713666180807143606","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Irritable bowel syndrome (IBS) is the most frequently diagnosed functional gastrointestinal disorder. It is characterised by abdominal pain, bloating and changes in bowel habits that can have a serious impact on the patient's quality of life. Treatment strategies are based on the nature and severity of the symptoms, the degree of functional impairment of the bowel habits, and the presence of psychosocial disorders. The purpose of this review is to update our current knowledge of therapeutic approach of this disorder.</p><p><strong>Method: </strong>A literature search for IBS therapy was carried out using the online databases of Pubmed, Medline and Cochrane.</p><p><strong>Results: </strong>An ideal treatment begins by explaining this condition and providing reassurance to the patients. There is limited evidence for the efficacy, and tolerability of the therapies currently available for the treatment of IBS. There is also a limited availability of pharmacological agents licensed specifically for the treatment of IBS subtypes, although new agents have been recently proposed to this goal. Furthermore, patients often associate their complaints with the ingestion of foods containing FODMAPs (fermentable oligo-di-monosaccharides, and polyols) and gluten derivates and a personalized diet can be proposed. However, more severe symptoms can be associated with greater levels of psychosocial problems and a psychological approach and antidepressant drugs can be needed.</p><p><strong>Conclusion: </strong>The treatment of IBS remains focused on treating the patient's predominant, or most troublesome, symptoms. New promising treatments have recently become available for the treatment of IBS but long term studies are still needed.</p>","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":"{\"title\":\"Therapeutic Approach for Irritable Bowel Syndrome: Old and New Strategies.\",\"authors\":\"Paolo Usai-Satta,&nbsp;Massimo Bellini,&nbsp;Mariantonia Lai,&nbsp;Francesco Oppia,&nbsp;Francesco Cabras\",\"doi\":\"10.2174/1574884713666180807143606\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Irritable bowel syndrome (IBS) is the most frequently diagnosed functional gastrointestinal disorder. It is characterised by abdominal pain, bloating and changes in bowel habits that can have a serious impact on the patient's quality of life. Treatment strategies are based on the nature and severity of the symptoms, the degree of functional impairment of the bowel habits, and the presence of psychosocial disorders. The purpose of this review is to update our current knowledge of therapeutic approach of this disorder.</p><p><strong>Method: </strong>A literature search for IBS therapy was carried out using the online databases of Pubmed, Medline and Cochrane.</p><p><strong>Results: </strong>An ideal treatment begins by explaining this condition and providing reassurance to the patients. There is limited evidence for the efficacy, and tolerability of the therapies currently available for the treatment of IBS. There is also a limited availability of pharmacological agents licensed specifically for the treatment of IBS subtypes, although new agents have been recently proposed to this goal. Furthermore, patients often associate their complaints with the ingestion of foods containing FODMAPs (fermentable oligo-di-monosaccharides, and polyols) and gluten derivates and a personalized diet can be proposed. However, more severe symptoms can be associated with greater levels of psychosocial problems and a psychological approach and antidepressant drugs can be needed.</p><p><strong>Conclusion: </strong>The treatment of IBS remains focused on treating the patient's predominant, or most troublesome, symptoms. New promising treatments have recently become available for the treatment of IBS but long term studies are still needed.</p>\",\"PeriodicalId\":10746,\"journal\":{\"name\":\"Current clinical pharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current clinical pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1574884713666180807143606\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current clinical pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574884713666180807143606","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 14

摘要

背景:肠易激综合征(IBS)是最常见的功能性胃肠道疾病。它的特点是腹痛、腹胀和排便习惯的改变,这些会严重影响患者的生活质量。治疗策略取决于症状的性质和严重程度、排便习惯的功能损害程度以及是否存在社会心理障碍。这篇综述的目的是更新我们目前对这种疾病的治疗方法的认识。方法:采用Pubmed、Medline和Cochrane在线数据库检索IBS治疗相关文献。结果:理想的治疗首先要解释这种情况,并向患者提供保证。目前用于治疗肠易激综合征的治疗方法的疗效和耐受性证据有限。尽管最近有人提出了新的药物,但专门用于治疗IBS亚型的药物的可用性也有限。此外,患者经常将他们的抱怨与摄入含有FODMAPs(可发酵的低聚二单糖和多元醇)和麸质衍生物的食物联系起来,可以提出个性化的饮食。然而,更严重的症状可能与更严重的社会心理问题有关,因此可能需要心理治疗和抗抑郁药物。结论:肠易激综合征的治疗仍然集中在治疗患者的主要或最麻烦的症状。最近出现了治疗肠易激综合症的新疗法,但仍需要长期研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Therapeutic Approach for Irritable Bowel Syndrome: Old and New Strategies.

Background: Irritable bowel syndrome (IBS) is the most frequently diagnosed functional gastrointestinal disorder. It is characterised by abdominal pain, bloating and changes in bowel habits that can have a serious impact on the patient's quality of life. Treatment strategies are based on the nature and severity of the symptoms, the degree of functional impairment of the bowel habits, and the presence of psychosocial disorders. The purpose of this review is to update our current knowledge of therapeutic approach of this disorder.

Method: A literature search for IBS therapy was carried out using the online databases of Pubmed, Medline and Cochrane.

Results: An ideal treatment begins by explaining this condition and providing reassurance to the patients. There is limited evidence for the efficacy, and tolerability of the therapies currently available for the treatment of IBS. There is also a limited availability of pharmacological agents licensed specifically for the treatment of IBS subtypes, although new agents have been recently proposed to this goal. Furthermore, patients often associate their complaints with the ingestion of foods containing FODMAPs (fermentable oligo-di-monosaccharides, and polyols) and gluten derivates and a personalized diet can be proposed. However, more severe symptoms can be associated with greater levels of psychosocial problems and a psychological approach and antidepressant drugs can be needed.

Conclusion: The treatment of IBS remains focused on treating the patient's predominant, or most troublesome, symptoms. New promising treatments have recently become available for the treatment of IBS but long term studies are still needed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current clinical pharmacology
Current clinical pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
3.60
自引率
0.00%
发文量
0
期刊介绍: Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal"s aim is to publish the highest quality review articles in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信